Difference between revisions of "Ipilimumab (Yervoy)"
m |
m |
||
Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *3/25/2011: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm FDA approved] "for the treatment of unresectable or metastatic melanoma." | + | *3/25/2011: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm FDA approved] "for the treatment of unresectable or metastatic [[Melanoma | melanoma]]." |
==Also known as== | ==Also known as== | ||
Line 33: | Line 33: | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
+ | |||
+ | [[Category:Drugs FDA approved in 2011]] |
Revision as of 15:34, 8 November 2014
General information
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ipilimumab (Yervoy) package insert[1]
- Ipilimumab (Yervoy) patient drug information (Chemocare)[5]
- Ipilimumab (Yervoy) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 3/25/2011: FDA approved "for the treatment of unresectable or metastatic melanoma."
Also known as
BMS-734016 or MDX-010.
References
- ↑ 1.0 1.1 1.2 Ipilimumab (Yervoy) package insert
- ↑ Ipilimumab (Yervoy) package insert (locally hosted backup)
- ↑ Yervoy manufacturer's website
- ↑ YERVOY Risk Evaluation and Mitigation Strategy (REMS) Site
- ↑ Ipilimumab (Yervoy) patient drug information (Chemocare)
- ↑ Ipilimumab (Yervoy) patient drug information (UpToDate)